Batoclimab is under clinical development by HanAll Biopharma and currently in Phase I for Pemphigus Vulgaris. According to GlobalData, Phase I drugs for Pemphigus Vulgaris have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Batoclimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Batoclimab overview

Batoclimab is under development for the treatment of idiopathic thrombocytopenic purpura (ITP), membranous nephropathy, pemphigus vulgaris, lupus nephritis (LN), myasthenia gravis (MG), Graves' ophthalmopathy, chronic inflammatory demyelinating polyneuropathy (CIDP), Graves disease (GD) and neuromyelitis optica (NMO). It is a fully human monoclonal antibody IgG1 targeting the Fc neonatal receptor (FcRn). It is administered subcutaneously and developed based on OmniAb technology. 

It was under development for warm autoimmune hemolytic anemia.

HanAll Biopharma overview

HanAll Biopharma (HanAll), formerly HanAll Pharmaceutical, is a developer of generic and specialty drugs for treatment of diseases related to digestive, endocrine, musculoskeletal and urinary system. The company’s pipeline products include HL036, a drug being developed for treating dry eye diseases; HL189 against non-infectious uveitis; IM156 targeting cancers; and HL190 to treat wet age-related macular degeneration. It also sells drugs for treating digestive dysfunction, osteoporosis, liver dysfunction, hepatic coma, metabolic disorders caused due to hypocalcemia, tetania, bone pain and also bone lesions. HanAll also conducts research for developing drugs in the therapeutic areas of autoimmune, eye diseases and immuno oncology indications. The company works in partnership with global pharmaceutical companies and academic institutions for advancing its pipeline products. It has operations in South Korea and the US. HanAll is headquartered in Seoul, South Korea

For a complete picture of Batoclimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.